Vaishali Pharma Ltd (NSE: VAISHALI) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹91 Cr, it ranks #3,322 by market cap among the 6,197 Indian listed companies on FinBizNet, and #69 of 86 in Medicinal Chemicals and Botanical Products. At ₹7.11 (as of 16 Nov 2026), the share price is 28.0% below its 52-week high of ₹9.87 and 49.7% above its 52-week low of ₹4.75. The share price is down 28.2% over one year and down 16.5% over three months.
| Current Price | ₹7.11 |
|---|---|
| Market Cap | ₹91 Cr |
| NSE Symbol | VAISHALI |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 22.1 |
| Return on Equity | 1.52% |
| Return on Assets | 1.88% |
| 52-Week Range | ₹4.75 – ₹9.87 |
| 1-Year Price Change | -28.2% |
| 3-Month Price Change | -16.5% |
| Beta (1Y) | 0.31 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.vaishalipharma.com |
| Revenue | ₹30 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 6.8% |
| EPS (Basic) | ₹0.16 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vaishali Pharma Ltd reported revenue of ₹30 Cr in Q2 FY27, down 9.8% from ₹33 Cr in Q2 FY26 and up 31.8% from ₹23 Cr in Q1 FY27. It posted a net profit of ₹2 Cr for the quarter, against a net profit of ₹1 Cr in Q2 FY26 (up 74.6%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹23 Cr (Q1 FY27) to ₹33 Cr (Q2 FY26). The company was profitable in each of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹30 Cr | ₹2 Cr | 6.8% |
| Q1 FY27 | ₹23 Cr | ₹1 Cr | 6.5% |
| Q4 FY26 | ₹27 Cr | ₹0 Cr | 1.4% |
| Q3 FY26 | ₹25 Cr | ₹1 Cr | 5.3% |
| Q2 FY26 | ₹33 Cr | ₹1 Cr | 3.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 31.61% of Vaishali Pharma Ltd's shares as of Sept 2026, unchanged from Dec 2025. Delivery averaged 72.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutica
1. Sale of Pharmaceutical Products-This segment offers pharmaceutical formulations, active pharmaceutical ingredients, surgical products, veterinary supplements, and herbal and nutraceutical products.
1. Sale of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Vaishali Pharma Ltd | ₹91 Cr | 22.1 | 1.52% | ₹30 Cr | -28.2% |
Listed by market capitalisation. Ratios are shown for context only.
Vaishali Pharma Ltd is trading at ₹7.11, with a market capitalisation of ₹91 Cr.
Vaishali Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Vaishali Pharma Ltd has a P/E of 22.1 and a return on equity of 1.52%.
Vaishali Pharma Ltd is listed on the NSE under the symbol VAISHALI.
Vaishali Pharma Ltd's share price is down 28.2% over one year and down 16.5% over three months. Its 52-week range is ₹4.75 to ₹9.87.
In Q2 FY27, Vaishali Pharma Ltd reported revenue of ₹30 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.16 (consolidated, parsed from the company's exchange filing).
Vaishali Pharma Ltd reported revenue of ₹30 Cr in Q2 FY27, down 9.8% from ₹33 Cr in Q2 FY26 and up 31.8% from ₹23 Cr in Q1 FY27.
Promoters held 31.61% of Vaishali Pharma Ltd's shares as of Sept 2026, unchanged from Dec 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.